StockNews.AI
PYXS
StockNews.AI
139 days

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

1. Lara S. Sullivan will speak at the Stifel Oncology Forum on April 9. 2. Pyxis focuses on innovative therapies for tough cancers with significant market potential. 3. Lead candidate MICVO is advancing in Phase 1 trials for difficult solid tumors. 4. Company plans one-on-one investor meetings to engage potential stakeholders. 5. MICVO targets key cancer mechanisms, suggesting strong anti-tumor capabilities.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive investor engagement and ongoing clinical trials may boost investor confidence, similar to other biotech firms seeing gains from successful trials or events. For example, companies announcing pivotal study success often experience stock price increases.

How important is it?

The news highlights key corporate actions and clinical developments, likely to affect investor perceptions and stock performance.

Why Short Term?

The upcoming investor forum may lead to immediate stock interest. Historical examples show that investor days can significantly impact stock performance within weeks.

Related Companies

ABEONTRACRMD
April 02, 2025 07:30 ET  | Source: Pyxis Oncology BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 11:30 a.m. ET. The Company will also be holding one-on-one investor meetings at the event. A live webcast and replay of the fireside chat will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com. About Pyxis Oncology, Inc.Pyxis Oncology, Inc. is a clinical-stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential as differentiated mono and combination therapies. The lead product candidate, micvotabart pelidotin (“MICVO” formerly PYX-201), is an antibody-drug conjugate (ADC) that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO has been evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors with a go-forward development focus on treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the strength of the HNSCC signal that emerged. MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. To learn more, visit www.pyxisoncology.com or follow us on X (formerly known as Twitter) and LinkedIn. Pyxis Oncology ContactPamela Connealy CFO and COO ir@pyxisoncology.com

Related News